c-MET

C-Met inhibitor,potent and selective

Potent c-Met inhibitor

C-Met inhibitor,potent and ATP-competitive

C-Met inhibitor,ATP-competitive

C-Met inhibitor,potent and highly selective

C-Met inhibitor,selective and ATP-competitive

Tivantinib (ARQ 197) is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM.

C-Met inhibitor,potent and selective

INCB28060 is a highly potent and orally bioavailable c-Met inhibitor with an IC₅₀ value of 0.13nM. INCB28060 is used to treat adults with metastatic non-small cell lung cancer (NSCLC), including those with NSCLC harboring mutations caused by MET exon 14 skipping.

EMD-1214063 (Tepotinib, MSC2156119J) is a novel potent and highly selective reversible, ATP-competitive small molecule c-Met inhibitor .

LY2801653 (Merestinib) is a potent, orally bioavailable c-Met inhibitor (IC 50 =4.7nM; K i value=2nM), with K D values of 20nM, 92nM, and 54nM for NTRK1, NTRK2, and NTRK3, respectively.

inhibitor of the c-Met kinase and the NPM-ALK

Potent MTH1 inhibitor

MGCD-265 is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 has significant antitumor activity.

BMS-777607 is a pan-TAMkinase inhibitor with IC 50 values of 3.9Nm, 1.1nM, 1.8nM, and 4.3nM for Met, Axl, Ron, and Tyro3, respectively.

MET inhibitor

A c-MET and ALK receptor tyrosine kinase inhibitor

antibiotic

SU5416 is a small-molecule Flk-1/KDR inhibitor that inhibits autophosphorylation of the Flk-1 receptor, with an IC 50 value of 1.23μM.

MET inhibitor

MET inibitor, highly selective, ATP-competitive

A c-Met inhibitor

Foretinib (GSK1363089) is a multi-target receptor tyrosine kinase inhibitor. Foretinib primary targets include c-Met (IC₅₀=0.4nM) and VEGFR2 (IC₅₀=0.9nM).